United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 7,061 shares of the firm’s stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $121.12, for a total value of $855,228.32. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
United Therapeutics Corporation (NASDAQ UTHR) traded up $1.40 during trading hours on Friday, hitting $123.02. The company had a trading volume of 297,623 shares, compared to its average volume of 564,104. United Therapeutics Corporation has a fifty-two week low of $112.01 and a fifty-two week high of $169.89. The firm has a market cap of $5,260.00, a price-to-earnings ratio of 10.46 and a beta of 1.38.
United Therapeutics Corporation (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share for the quarter, beating the Zacks’ consensus estimate of $4.01 by $2.26. United Therapeutics Corporation had a return on equity of 26.24% and a net margin of 30.50%. The business had revenue of $445.50 million during the quarter, compared to analyst estimates of $426.43 million. During the same quarter last year, the company posted $4.23 EPS. United Therapeutics Corporation’s revenue for the quarter was up 9.1% on a year-over-year basis. sell-side analysts expect that United Therapeutics Corporation will post 11.92 EPS for the current fiscal year.
WARNING: “Insider Selling: United Therapeutics Corporation (UTHR) CEO Sells 7,061 Shares of Stock” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2017/11/17/insider-selling-united-therapeutics-corporation-uthr-ceo-sells-7061-shares-of-stock.html.
Several large investors have recently added to or reduced their stakes in the stock. HPM Partners LLC boosted its position in shares of United Therapeutics Corporation by 0.8% in the 2nd quarter. HPM Partners LLC now owns 1,981 shares of the biotechnology company’s stock valued at $257,000 after purchasing an additional 15 shares during the period. First Allied Advisory Services Inc. lifted its stake in United Therapeutics Corporation by 0.4% in the 2nd quarter. First Allied Advisory Services Inc. now owns 4,579 shares of the biotechnology company’s stock worth $598,000 after acquiring an additional 19 shares in the last quarter. Fisher Asset Management LLC lifted its stake in United Therapeutics Corporation by 1.4% in the 2nd quarter. Fisher Asset Management LLC now owns 3,169 shares of the biotechnology company’s stock worth $411,000 after acquiring an additional 45 shares in the last quarter. Synovus Financial Corp lifted its stake in United Therapeutics Corporation by 1.2% in the 2nd quarter. Synovus Financial Corp now owns 5,639 shares of the biotechnology company’s stock worth $731,000 after acquiring an additional 69 shares in the last quarter. Finally, Ifrah Financial Services Inc. lifted its stake in United Therapeutics Corporation by 1.7% in the 2nd quarter. Ifrah Financial Services Inc. now owns 4,437 shares of the biotechnology company’s stock worth $576,000 after acquiring an additional 76 shares in the last quarter.
UTHR has been the topic of a number of research analyst reports. Zacks Investment Research raised United Therapeutics Corporation from a “strong sell” rating to a “hold” rating in a report on Monday, October 9th. ValuEngine raised United Therapeutics Corporation from a “hold” rating to a “buy” rating in a report on Monday, October 2nd. HC Wainwright reaffirmed a “hold” rating and set a $95.00 target price on shares of United Therapeutics Corporation in a research note on Thursday, October 26th. Cowen and Company reaffirmed a “hold” rating and set a $129.00 target price on shares of United Therapeutics Corporation in a research note on Friday, October 27th. Finally, Oppenheimer Holdings, Inc. reaffirmed a “buy” rating on shares of United Therapeutics Corporation in a research note on Friday, September 8th. Five investment analysts have rated the stock with a sell rating, seven have issued a hold rating and three have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $132.82.
United Therapeutics Corporation Company Profile
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.